Drug intelligence / Profile preview

KRIYA-296

Development stage: Preclinical
Lead developer: Kriya Therapeutics
Modality: Gene Therapies

Overview

KRIYA-296 is a gene therapy candidate currently in the research phase of development at Kriya Therapeutics. As of early 2024, the company has not disclosed the specific biological target, mechanism of action, or the primary disease indication for this program. Kriya Therapeutics utilizes a proprietary platform to develop gene therapies for prevalent diseases, and KRIYA-296 represents one of their early-stage assets within this pipeline.

Beyond the preview

Go deeper on KRIYA-296.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRIYA-296.

Explore the full profile